Syros Pharmaceuticals reports Q4 EPS ($2.18), consensus ($1.14)

Reports Q4 revenue $387,000, consensus $2M. “We are entering 2024 poised for a major transformation,” said Conley Chee, CEO of Syros. “We recently completed enrollment of the 190 patients necessary for our primary endpoint analysis in the SELECT-MDS-1 Phase 3 trial, and we remain on track to report pivotal CR data by the middle of the fourth quarter of this year. We are optimistic about this data, which we believe will further reinforce tamibarotene’s potential as a differentiated, biologically targeted approach for the approximately 50% of HR-MDS patients who are positive for RARA overexpression.”